Fatty Liver News and Research

Latest Fatty Liver News and Research

AGA's journals highlight important updates into treatments for cirrhosis, NAFLD

Cirrhosis and nonalcoholic fatty liver disease (NAFLD) are two serious liver conditions with limited pharmacological treatments. The December issues of AGA's journals -- Clinical Gastroenterology and Hepatology and Gastroenterology -- highlight important updates into treatments for these two debilitating diseases.

23 Nov 2014

Research finding points to potential new treatment for metabolic disorders

Researchers at the University of Michigan have discovered how a previously unknown hormone serves as a messenger from fat cells to the liver and are investigating the potential of developing a new treatment for metabolic disorders.

17 Nov 2014

Resonance Health launches new diagnostic imaging solution for patients with fatty liver disease

ASX listed Resonance Health officially launched an innovative new diagnostic imaging solution for liver patients worldwide at the American Association for the Study of Liver Diseases annual conference in Boston this week.

10 Nov 2014

MGH, MIT partner to accelerate development of diagnostic tools and therapies

A novel partnership between Massachusetts General Hospital and Massachusetts Institute of Technology is addressing three major challenges in clinical medicine – improving the diagnosis of disease, developing new approaches to prevent and treat infectious and autoimmune diseases, and developing more accurate methods of diagnosing and treating major neurodegenerative and psychiatric diseases. While individual collaborations between MGH and MIT investigators are nothing new, this formalized strategic partnership is designed to accelerate the development of diagnostic tools and therapies.

16 Oct 2014

Decaffeinated coffee may benefit liver health

Researchers from the National Cancer Institute report that decaffeinated coffee drinking may benefit liver health. Results of the study published in Hepatology, a journal of the American Association for the Study of Liver Diseases, show that higher coffee consumption, regardless of caffeine content, was linked to lower levels of abnormal liver enzymes. This suggests that chemical compounds in coffee other than caffeine may help protect the liver.

10 Oct 2014

Galmed Pharmaceuticals purchases EndoPAT devices, accessories from Itamar Medical

Galmed Pharmaceuticals Ltd. ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral medication for the treatment of liver diseases and cholesterol gallstones, announced today that it purchased 60 EndoPAT™ devices and accessories from Itamar Medical Ltd.

29 Sep 2014

Pitt researchers awarded new $5.8 million NIH grant to develop microfluidic 3D liver model system

With a new $5.8 million, three-year award from the National Institutes of Health, researchers at the University of Pittsburgh School of Medicine will further develop a state-of-the-art, microfluidic 3D model system that mimics structure and function of the liver to better predict organ physiology, assess drug toxicity and build disease models.

25 Sep 2014

Highlights: Hawaii public hospital cuts; La. struggles with state worker health program costs; aging in Ky.

Public hospitals across Hawaii are finding ways to reduce staff and cut services because they don't have enough money to make ends meet. Executives from the Hawaii Health Systems Corp. told lawmakers Friday that even after layoffs they are facing a $30 million deficit in 2015. One hospital on Maui chose to close its adolescent psychology unit because it couldn't sustain the appropriate staffing levels to provide the services. It's also considering cuts to oncology and dialysis services if the situation doesn't improve (9/20).

23 Sep 2014

Adequate levels of vitamin E critical for young, elderly and pregnant women

Amid conflicting reports about the need for vitamin E and how much is enough, a new analysis published today suggests that adequate levels of this essential micronutrient are especially critical for the very young, the elderly, and women who are or may become pregnant.

16 Sep 2014

Research findings call for clinical testing of relevant drugs to prevent NASH

Non-alcoholic fatty liver disease (NAFLD) is a common affliction, affecting almost 30 percent of Americans, with a significant number suffering from its most severe form, called non-alcoholic steatohepatitis or NASH, which can lead to cirrhosis and liver cancer. In recent years, NASH has become the leading cause of liver transplantation.

19 Aug 2014

Researchers examine effects of bacteria in fighting against obesity

A probiotic that prevents obesity could be on the horizon. Bacteria that produce a therapeutic compound in the gut inhibit weight gain, insulin resistance and other adverse effects of a high-fat diet in mice, Vanderbilt University investigators have discovered.

26 Jul 2014

Unique bacterial biomarkers may help develop diagnostics, treatments for liver cirrhosis

ENTEROME Bioscience SA, a pioneer in the development of innovative disease management solutions based on a deep understanding of the gut microbiome, and with a strong focus on liver diseases, highlights the advanced online publication in Nature of a research paper describing the identification of a unique series of bacterial biomarkers that could provide new opportunities for the development of diagnostics and treatments for liver cirrhosis.

26 Jul 2014

Galmed reports net loss of $3.9 million for six months ended June 30, 2014

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones, today announced financial results for the period ended June 30, 2014.

25 Jul 2014

Drug for reduction of abdominal fat in HIV patients may also reduce fatty liver disease

The only drug to receive FDA approval for reduction of the abdominal fat deposits that develop in some patients receiving antiviral therapy for HIV infection may also reduce the incidence of fatty liver disease in such patients.

21 Jul 2014

Growth hormone reduces liver fat in HIV-infected patients with excess abdominal fat

In a preliminary study, HIV-infected patients with excess abdominal fat who received the growth hormone-releasing hormone analog tesamorelin for 6 months experienced modest reductions in liver fat, according to a study in the July 23/30 issue of JAMA, a theme issue on HIV/AIDS.

21 Jul 2014

Fatty Liver News and Research

Latest Fatty Liver News and Research

AGA's journals highlight important updates into treatments for cirrhosis, NAFLD

Research finding points to potential new treatment for metabolic disorders

Resonance Health launches new diagnostic imaging solution for patients with fatty liver disease

MGH, MIT partner to accelerate development of diagnostic tools and therapies

Decaffeinated coffee may benefit liver health

Galmed Pharmaceuticals purchases EndoPAT devices, accessories from Itamar Medical

Pitt researchers awarded new $5.8 million NIH grant to develop microfluidic 3D liver model system

Highlights: Hawaii public hospital cuts; La. struggles with state worker health program costs; aging in Ky.

Adequate levels of vitamin E critical for young, elderly and pregnant women

Research findings call for clinical testing of relevant drugs to prevent NASH

Researchers examine effects of bacteria in fighting against obesity

Unique bacterial biomarkers may help develop diagnostics, treatments for liver cirrhosis

Galmed reports net loss of $3.9 million for six months ended June 30, 2014

Drug for reduction of abdominal fat in HIV patients may also reduce fatty liver disease

Growth hormone reduces liver fat in HIV-infected patients with excess abdominal fat

Consumption of probiotics during 30 days helps diminish accumulation of fat in liver

Heavy drinkers at greater risk of developing pneumonia and ARDS

Alcoholic liver disease: an interview with Dr Vinood Patel, University of Westminster

Researchers shown how free radicals contribute to fatty liver disease

Continuation of metformin after cirrhosis diagnosis improves survival rates in diabetes patients

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Fatty Liver News and Research

Latest Fatty Liver News and Research

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in